Expertise in
24
conditions

Dr. Brian R. Hu

Urology
Riverside University Health System-Medical Center
26520 Cactus Ave, 
Moreno Valley, CA 
Offers Telehealth
Expertise in
24
conditions
Riverside University Health System-Medical Center
26520 Cactus Ave, 
Moreno Valley, CA 

Overview

Brian Hu is a Urologist practicing medicine in Moreno Valley, California.

Dr. Hu is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

He is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 7 clinical trials.

Specialties

Urology

Licenses

Urology in CA

Hospital Affiliations

Loma Linda University Medical Center
Arrowhead Regional Medical Center
Riverside University Health System-Medical Center
Redlands Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Riverside University Health System-Medical Center
26520 Cactus Ave, Moreno Valley, CA 92555

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Procedure, Other
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other, Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

55 Total Publications

Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes.
Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes.
Journal: Urologic oncology
Published: January 25, 2026
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Office

1516 San Pablo St Ste 3500, 
Los Angeles, CA 
 (59.0 miles away)
323-865-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Siamak Daneshmand is a Urologist practicing medicine in Los Angeles, California. Dr. Daneshmand is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Testicular Cancer, Cystectomy, and Bladder Reconstruction.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (58.7 miles away)
323-865-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hooman Djaladat is a Urologist practicing medicine in Los Angeles, California. Dr. Djaladat is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

USC Norris Comprehensive Cancer Center And Hospital

1441 Eastlake Ave, 
Los Angeles, CA 
 (58.7 miles away)
323-865-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Inderbir Gill is a Urologist practicing medicine in Los Angeles, California. Dr. Gill is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Cystectomy.

Frequently Asked Questions about Dr. Brian R. Hu

How do I make an appointment with Dr. Brian R. Hu?

You can book an appointment with Dr. Brian R. Hu by calling their office at 951-486-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brian R. Hu a top-rated expert for Testicular Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brian R. Hu is classified as an Distinguished expert for Testicular Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brian R. Hu specialize in?

While Dr. Brian R. Hu is a Urology, they have specific expertise in Testicular Cancer, Bladder Cancer, and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Brian R. Hu participate in research or clinical trials?

Yes. Dr. Brian R. Hu has published 55 articles and abstracts on conditions like Testicular Cancer. You can view a list of Dr. Brian R. Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brian R. Hu accept my insurance?

Dr. Brian R. Hu accepts most major insurance plans, including Alignment Health Plan and Anthem BCBS. We recommend calling the office directly at 951-486-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile